Insider Selling: AtriCure (NASDAQ:ATRC) Director Sells $946,000.00 in Stock

Posted by Brian Himes on Aug 2nd, 2026

AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the completion of the sale, the director owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This trade represents a 38.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AtriCure Trading Down 6.0%

ATRC opened at $37.76 on Friday. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of 179.82 and a beta of 1.24. The company has a quick ratio of 3.18, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $43.18. The company has a 50-day simple moving average of $31.10 and a 200 day simple moving average of $31.34.

AtriCure (NASDAQ:ATRC – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same period in the previous year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts predict that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ATRC. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Canaccord Genuity Group lifted their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Zacks Research raised AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday. Finally, UBS Group reduced their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

View Our Latest Stock Analysis on ATRC

Institutional Investors Weigh In On AtriCure

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Oak Harvest Investment Services bought a new position in AtriCure in the fourth quarter valued at about $1,484,000. Massachusetts Financial Services Co. MA grew its holdings in shares of AtriCure by 20.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 511,213 shares of the medical device company’s stock worth $20,224,000 after purchasing an additional 86,532 shares during the last quarter. F m Investments LLC bought a new stake in shares of AtriCure during the fourth quarter worth about $2,872,000. Vanguard Group Inc. increased its stake in shares of AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after buying an additional 62,861 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of AtriCure in the first quarter valued at approximately $7,922,000. Institutional investors own 99.11% of the company’s stock.

AtriCure News Summary

Here are the key news stories impacting AtriCure this week:

Positive Sentiment: AtriCure’s recent second-quarter results exceeded expectations, with earnings per share of $0.18 versus the $0.13 analyst estimate and revenue of $153.6 million versus $151.8 million expected. The company also improved from a year-ago loss, supporting its growth and profitability outlook. AtriCure second-quarter results presentation
Positive Sentiment: UBS lowered its price target from $55 to $50 but retained a Buy rating. The revised target still indicates meaningful potential upside and suggests the analyst remains constructive on AtriCure’s medical-device business. UBS AtriCure price target report
Neutral Sentiment: Options-market coverage points to the possibility of a significant upcoming move in ATRC, but the available information does not establish whether traders are positioning for a rise or decline. Elevated options activity could contribute to short-term volatility. AtriCure options activity article
Neutral Sentiment: New share-registration filings may give AtriCure additional financing flexibility. However, investors may monitor the filings for potential future share issuance and dilution. AtriCure share registration article
Negative Sentiment: Insiders sold approximately $1.42 million of AtriCure shares. Director Sven Wehrwein reduced his position by about 38%, while insiders Justin J. Noznesky and Vinayak Doraiswamy each sold roughly 6% of their holdings. The clustered selling may weigh on sentiment, particularly after ATRC’s strong advance toward its 52-week high. AtriCure insider selling report

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.